Welcome to our dedicated page for Zivo Bioscience SEC filings (Ticker: ZIVOW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
zivo bioscience, inc., a u.s.-based r&d firm, is dedicated to the study, development and commercialization of natural nutritional compounds and bioactive molecules derived from proprietary algal strains.ZIVO Bioscience (ZIVO) filed its Q3 2025 10‑Q, showing modest revenue growth alongside tight liquidity and continued losses. Revenue was $65,625, up from $31,500, with gross margin of $21,288. The company reported a net loss of $1,033,056 for the quarter and operating cash outflow of $2,173,204 for the nine months.
Cash declined to $57,222 with total liabilities of $3,846,055 and a stockholders’ deficit of $(3,286,603). Shares outstanding were 3,832,327 as of September 30, 2025, and 3,888,595 as of November 9, 2025. Management states there is substantial doubt about the ability to continue as a going concern and estimates needing about $6.0 million over the next 12 months to fund basic operations.
During 2025, ZIVO raised funds via private equity and debt, including a $250,000 convertible note at 10% with warrants to purchase 1,793 shares at $13.94. Subsequent to quarter‑end (October 2025), the company sold 54,168 shares and 3,091 warrants, raising $390,000 in cash and exchanging $284,433 of related party payables. Material weaknesses in internal control over financial reporting persist.
FAQ
What is the current stock price of Zivo Bioscience (ZIVOW)?
